Evaluation of the mechanism underlying melatonin action in cholestatic liver disease treatment via network pharmacology, molecular docking, and in vivo experiments
Fig 2
Identification and interaction of potential targets.
(A) Venn diagram showing the 96 overlapping targets between melatonin and cholestatic liver disease. (B) Protein-protein interaction (PPI) network of the overlapping targets, with nodes representing proteins and edges representing interactions.